Skip to main
HAE
HAE

Haemonetics (HAE) Stock Forecast & Price Target

Haemonetics (HAE) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 56%
Buy 22%
Hold 22%
Sell 0%
Strong Sell 0%

Bulls say

Haemonetics Corp is experiencing strong financial momentum, with a projected FY25 operating margin of approximately 24%, reflecting consistent improvement from previous years. The company's gross margin has increased by 240 basis points year-over-year, and its operating margin has risen significantly by 390 basis points, demonstrating effective cost management and operational efficiency. Strong revenue growth in the plasma segment, driven by premium pricing and increased market share, alongside double-digit growth in transfusion management, underscores the company’s robust growth potential in key segments.

Bears say

Haemonetics Corp has experienced a decline in its Blood Center and Plasma segment sales, with Blood Center sales down 2.8% to $68.5 million and Plasma sales declining 9.1% to $138.6 million, both indicating a troubling trend in revenue generation. Additionally, the company's revised guidance for FY25 reflects lower growth expectations, projecting Hospital growth at 12-14%, down from 14-17%, and a significant adjustment in Blood Center growth expectations from a previous range of (3-6%) to (5-7%). Moreover, overall organic revenue growth has slowed to (0.3%) in F3Q25, compared to 3.7% in F2Q25, suggesting deteriorating operational performance and potential challenges in maintaining margins and earnings in the near future.

Haemonetics (HAE) has been analyzed by 18 analysts, with a consensus rating of Buy. 56% of analysts recommend a Strong Buy, 22% recommend Buy, 22% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Haemonetics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Haemonetics (HAE) Forecast

Analysts have given Haemonetics (HAE) a Buy based on their latest research and market trends.

According to 18 analysts, Haemonetics (HAE) has a Buy consensus rating as of Jul 28, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $83.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $83.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Haemonetics (HAE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.